1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028

Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028

  • June 2022
  • 1320 pages
  • ID: 6285414
  • Format: PDF
  • Kuick Research


Table of Contents

Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:

• Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
• Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
• Combination Cancer Immunotherapy Market By 15 Different Cancers
• Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
• Patent, Price & Dosage Analysis On Approved Combination Drugs
• Global & Regional Sales Insights On Approved Combination Drugs Till 2028
• Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
• Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
• Clinical Trials & Patent Insight By Company, Country, Indication & Phase

In recent years, cancer immunotherapy has emerged as an appealing strategy by overcoming the limitations of conventional therapies. The novel therapy aims to harness the ability of immune system to recognize, target, and destroy cancer cells. Cancer immunotherapy now encompasses several therapeutic agents including monoclonal antibodies, immune checkpoint inhibitors, vaccines, antibody drug conjugates, and others. All these novel approaches have their distinct target and mechanism of action. Although immunotherapies have shown significant improvement in clinical outcome of cancer patients, these are associated with several limitations. Tumor heterogeneity and development of resistance are the major challenges to current immunotherapeutic approaches.

This has pushed the research studies to evaluate immunotherapy in combination with other cancer targeting approaches including chemotherapy, radiotherapy, targeted drugs, and other immunotherapeutic approaches. The combination therapy aims to combine two or more drugs which have synergistic mechanism of action in targeting the disease. In comparison to monotherapy, combinational therapy aims to have more enhanced and additive effect in the targeting of cancer cells. Further, it also has the potential to overcome the drug resistance and enhance the overall survival rate in cancer patients. The conferred advantages associated with combinational therapies have drawn the interest of several pharmaceutical giants to invest in this segment.

Currently, several drugs such as Opdivo, Yervoy, Bevacizumab, and others have gained approval as combinational immunotherapy for the management of cancer cells In 2022, US FDA has granted approval to the fixed dose combination of relatlimab (LAG-3 inhibitor) plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma. The novel combination has shown manageable safety with no new or unexpected safety signals. The combination is sold under the trade name Opdualag and is marketed by Bristol Myers Squibb.

In last few years, pharmaceutical companies have begun to embrace a more collaborative way of working to mitigate the obstacles of drug development. The manufacturers of antibody drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge, and expand business. For instance, Gilead Sciences entered into two clinical trial collaboration and supply agreements with Merck to evaluate the combination of Trodelvy and Keytruda in first-line metastatic non-small cell lung cancer. Additionally, the companies recently established an agreement whereby Gilead will sponsor a phase-II signal seeking study evaluating combinations that include pembrolizumab in first line non-small cell lung cancer.

Triple combinational therapy is also gaining considerable momentum in the market. However, it is mainly confined to initial stages of clinical development. For instance, Zenith Pharmaceutical in collaboration with Bristol Myers Squibb is conducting clinical trial which is evaluating triple combination of ZEN-3694 (BET inhibitor), Opdio, and Yervoy. The trial will be conducted by NCI funded investigators and will evaluate the safety and activity of this combination in patients with solid tumors that have become resistant to other therapies. Apart from this, a triple combinational therapy of PD-1/PD-L1, BRAF, and MEK inhibitor is also ongoing in multiple myeloma patients.

As per our report findings, the global combinational immunotherapy market is expected to surpass US$ 15 Billion by 2028. This is mainly attributed to rising geriatric population and surge in prevalence of various cancers. This possesses high medical needs for the development of targeted therapies in its management. In addition, rising investments by pharmaceutical companies due to promising response of combinational immunotherapy is also driving the growth of market. The major players in the global combinational immunotherapy market include Amgen, Roche, Macrogenics, Mylan, Seagen, AstraZeneca, Gilead Sciences, GlaxoSmithKline, and others.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Cancer Vaccine Market & Clinical Trials Outlook 2028

  • $ 3300
  • July 2022
  • 600 pages

Global Cancer Vaccine Market & Clinical Trials Outlook 2028 Highlights: • Global and Regional Market Size Insight 2022 Till 2028 • Cancer Vaccine Market Insight & Forecast By 10 Countries 2022 Till ...

  • World
  • Cancer Immunotherapy
  • Industry analysis


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on